- Hemoglobin ≥80 g/L (may receive RBC transfusions) Patients with known bone marrow metastatic disease will be eligible for the study and may receive transfusions, provided ≤25% of bone marrow is involved, and provided they are not known to be refractory to red cell or platelet transfusions.